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Abstract
Background—Microsatellite instability (MSI) and BRAF-mutation status are associated with 
colorectal cancer survival whereas the role of body mass index (BMI) is less clear. We evaluated 
the association between BMI and colorectal cancer survival, overall and by strata of MSI, BRAF-
mutation, sex, and other factors.
Methods—This study included 5,615 men and women diagnosed with invasive colorectal cancer 
who were followed for mortality (maximum: 14.7 years; mean: 5.9 years). Pre-diagnosis BMI was 
derived from self-reported weight approximately 1-year before diagnosis and height. Tumor MSI 
and BRAF-mutation status were available for 4,131 and 4,414 persons, respectively. Multivariable 
hazard ratios (HR) and 95% confidence intervals (CIs) were estimated from delayed-entry Cox 
proportional hazards models.
Results—In multivariable models, high pre-diagnosis BMI was associated with higher risk of 
all-cause mortality in both sexes (per 5-kg/m2, HR = 1.10; 95% CI = 1.06 to 1.15), with similar 
associations stratified by sex (p-interaction: 0.41), colon vs rectum (p-interaction: 0.86), MSI 
status (p-interaction: 0.84), and BRAF-mutation status (p-interaction: 0.28). In joint models, with 
MS-stable/MSI-low and normal BMI as the reference group, risk of death was higher for MS-
stable/MSI-low and obese BMI (HR: 1.32; p-value: 0.0002), not statistically significantly lower 
for MSI-high and normal BMI (HR: 0.86; p-value: 0.29), and approximately the same for MSI-
high and obese BMI (HR: 1.00; p-value: 0.98).
Conclusions—High pre-diagnosis BMI was associated with increased mortality; this association 
was consistent across participant subgroups, including strata of tumor molecular phenotype.
Impact—High BMI may attenuate the survival benefit otherwise observed with MSI-high 
tumors.
Keywords
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Introduction
High body mass index (BMI) is an established risk factor for colorectal cancer (1–4); 
however, associations are usually stronger for men than women and for colon than rectal 
cancers (2–5). Emerging data suggest the BMI-colorectal cancer association differs by 
microsatellite instability (MSI) status (6–10), with stronger associations typically shown for 
MS-stable than MSI-high tumors and other tumor phenotypes correlated with MS-stable 
Campbell et al. Page 2













(11). The impact of BMI on mortality after colorectal cancer diagnosis is less clear, possibly 
owing to the timing of BMI evaluation relative to diagnosis (12–15). When BMI was 
evaluated in the peri- or post-diagnosis period, generally null or only modest associations 
were shown (10, 12–14, 16–23). In contrast, when pre-diagnosis BMI was evaluated, studies 
typically showed higher risks of all-cause and colorectal-cancer-specific mortality with high 
BMI (12–15, 24–26).
MSI is an established marker of colorectal cancer survival: patients with MSI-high tumors 
have a favorable prognosis compared to age- and stage-matched patients with MS-stable 
tumors (27–29). Similarly, patients with BRAF mutations, compared to patients with BRAF-
wildtype tumors, have poorer prognosis (29, 30). It is not known if BMI or other lifestyle 
and behavioral factors modify the influences of MSI or BRAF on survival; it is plausible 
that lifestyle factors, including BMI, may differentially influence survival of patients 
according to tumor molecular features since those factors likely interact with the tumor 
cells’ microenvironment.
Sub-group differences for the association between BMI and colorectal cancer incidence are 
consistently shown by strata of sex, site in the colorectum, and tumor molecular phenotype; 
however, it is not clear if these etiologic differences translate to the prognosis setting. This 
study examined the associations of BMI 2 years prior to enrollment (which is akin to BMI 
approximately 1 year prior to diagnosis, and referred to here as ‘pre-diagnosis recent BMI’), 
BMI at age 20 years, and adult weight change with all-cause and colorectal-cancer-specific 
mortality in a cohort of 5,615 adults who were diagnosed with incident, invasive colon or 
rectal adenocarcinoma. Additionally, we examined whether associations differed by strata of 
sex, tumor site in the colorectum, smoking, disease stage, MSI, BRAF, and other factors.
Materials and Methods
Study Population
Men and women in this study were identified from the Colon-Cancer Family Registry 
(Colon-CFR), an international resource for studies on colorectal cancer etiology and 
survival, initiated in 1997 (31). Case participants with incident colon or rectal cancer were 
identified via state or provincial cancer registries and invited to enroll. The mean time from 
diagnosis to enrollment for persons in this analysis was 0.92 years.
Of the 7,702 persons initially identified in the Colon-CFR that had returned an 
epidemiologic questionnaire, exclusions were made as follows: diagnosis prior to baseline in 
1997 (n=97); primary diagnosis with appendiceal or intestinal not-otherwise-specified 
cancer (n = 56); carcinoma in situ (n=29); missing age or date of enrollment (n=8); missing 
pre-diagnosis recent BMI (n=152); missing end-of-follow-up date (n=121); proxy 
respondent (n=124); less than 30 days of follow-up time (n=365); and time from diagnosis 
to enrollment greater than 2 years (n=1,135). Thus, 5,615 Colon-CFR enrollees were 
included in this analysis.
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Data on demographics, race/ethnicity, personal and family history of cancer, medical 
history, reproductive factors, physical activity, diet, alcohol, tobacco, body weight, and 
height were collected via standardized personal interviews, telephone interviews, and/or 
mailed questionnaires (8, 31). The questionnaires are available online (32). Two measures of 
self-reported body weight were requested: pre-diagnosis recent weight (queried as body 
weight 2 years prior to enrollment, which corresponds to approximately 1 year prior to 
cancer diagnosis) and weight at age 20 years. All persons were asked to provide current 
height. All co-variables used a pre-diagnosis referent period. After enrollment, the cohort 
was actively followed via periodic contact. Vital status, cause of death (COD), and date of 
death were ascertained through linkage with population-based registries, accrual of death 
certificates, contact with next-of-kin, and, more rarely, via other mechanisms (e.g., 
obituaries).
Written informed consent was obtained from all study participants and the institutional 
review boards at each center approved the studies.
Assessment of BMI and Adult Weight Change
Pre-diagnosis recent BMI was calculated from pre-diagnosis recent weight in kilograms (kg) 
divided by height in meters (m) squared; BMI at age 20 years was similarly calculated using 
weight at age 20 years. BMI was categorized according to World Health Organization 
criteria (33). Adult weight change was calculated as pre-diagnosis recent weight minus 
weight at age 20 years (both in kg).
Assessment of Tumor Characteristics
Tumor tissue from the Jeremy Jass Memorial Pathology Bank characterized the tumor MSI 
and BRAF mutational status of 4,131 and 4,414 persons, respectively. Persons without MSI 
(n = 1,484) were, on average, younger than those with tumor blocks (mean age at study 
enrollment: 53.2 vs 55.9 years; P<.0001); otherwise, there were no meaningful differences 
between those with and without MSI by sex, site, disease stage, or BMI. BRAF data were 
available for slightly more persons diagnosed with colon (79.8%) than rectal (76.3) cancer 
(P=0.003); otherwise no meaningful differences were noted.
DNA for molecular testing was extracted from formalin-fixed paraffin-embedded tissues 
with use of the QIAamp Tissue kit (Qiagen, Valencia, CA) according to the manufacturer’s 
instructions, as previously described (8). For the majority of case subjects with MSI 
(n=2,893), tumor MSI was assessed by polymerase chain reaction (PCR) assays with the use 
of four mononucleotide markers (BAT25, BAT26, BAT40, and BAT34C4), five 
dinucleotide markers (D5S346, D17S250, ACTC, D18S55, and D10S197), and one complex 
marker (MYCL) (8). Tumors were classified as MSI-high if ≥30% of the markers 
demonstrated instability (i.e., a change in marker repeat length was detected when 
comparing DNA from normal to tumor tissue), MSI-low if >0% and <30% demonstrated 
instability, and MS-stable if none exhibited instability (34). A minimum of four unequivocal 
results were required to characterize MSI. For a minority of persons (n=1,238), MSI status 
was determined via immunohistochemistry (IHC) of the mismatch repair proteins MLH1, 
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MSH2, MSH6 and PMS2. Positive staining for all proteins indicated MS-stable whereas 
absence of staining for any protein indicated MSI-high (35, 36). IHC-based methods for 
detecting MSI-high and MS-stable show very high sensitivity and specificity with PCR-
based methods (35). Tumor DNA was used to assess the BRAF c.1799 T>A (p.V600E) 
mutation using fluorescent allele-specific PCR, as described previously (37).
Colorectal cancer stage at the time of diagnosis was collected from state/provincial cancer 
registry information and/or from clinical/pathology records. When stage data were available 
both from registries and clinical/pathology records, the latter took precedence. Harmonized 
summary stage data were derived according to American Joint Committee on Cancer 
(AJCC) Tumor Node Metastasis (TNM) criteria (38) or converted from SEER summary 
stage to TNM summary stage using an algorithm (39). Participants who were missing one or 
more of the individual components required to derive TNM summary stage (i.e., depth of 
invasion of the primary tumor, T-stage; presence of metastases in regional lymph nodes, N-
stage; and presence of distant metastases, M-stage) were set to missing stage (20.7%).
Statistical Analysis
Multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were 
calculated using delayed-entry Cox proportional hazards models to estimate the associations 
of pre-diagnostic BMI and adult weight change with risk of death. Delayed-entry models 
accounted for the lag between diagnosis and enrollment. The time axis for all analyses was 
time since diagnosis and models were stratified on age at diagnosis. The proportional 
hazards assumption was tested with multiplicative interaction terms between BMI and time 
and Cox models with and without interaction terms were compared via the likelihood ratio 
test. Fully-adjusted models included smoking status, tumor stage, study center, and sex 
(combined models), as parameterized in Table 1. Missing covariables were treated as a 
separate category. Inclusion of physical activity, red meat intake, education, race, and 
aspirin made no appreciable differences to the HRs and were not included in the final 
models. Follow-up time ended with date of death or last contact.
For analyses of colorectal-cancer-specific mortality, follow-up time ended on the date of 
death from colon or rectal cancer as the primary underlying cause; persons who died from 
other causes or who were alive at last contact were censored in these analyses. Persons with 
unknown COD, and all persons enrolled in the USC/Stanford consortium (where no COD 
data were available), were excluded from the cause-specific analyses.
In categorical Cox models, persons who were underweight (<18.5 kg/m2), overweight (25–
29.9 kg/m2), and obese (≥30 kg/m2) were compared to persons with normal BMI (18.5–24.9 
kg/m2). Obesity was further stratified as classes I (30–34.9 kg/m2), II (35–39.9 kg/m2), and 
III (≥40 kg/m2) when the number of outcomes was greater than or equal to 10 per BMI 
category. Linear models examined the association of BMI, in 5 kg/m2 increments, with 
mortality, excluding the underweight category. Wald tests assessed linear trends. Restricted 
cubic splines assessed potential non-linearity of the relationship between BMI and all-cause 
mortality (40). For the cubic spline analysis, knots were selected at BMI values of 18.5, 22, 
25, 30 and 40 while the referent was set at 22. The likelihood ratio test assessed non-
linearity via a model that contained only the linear term to a model with the linear and the 
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cubic spline terms. Multiplicative interaction terms and the likelihood ratio test assessed 
whether the association between BMI and mortality differed by sex, MSI, BRAF, tumor site, 
smoking, and other factors. In sensitivity analyses, persons who were missing stage data 
were excluded. All P-values were two-sided; P-values less than 0.05 were considered 
statistically significant.
Results
In this cohort, 2,053 deaths occurred (1,233 deaths attributed to colorectal cancer, 533 
deaths attributed to other causes; COD was unavailable for 287 deaths) during a mean of 5.9 
years from study enrollment to end-of-study (minimum: 31 days; maximum: 14.7 years). Of 
the 2,053 deaths, the majority were verified through linkage with various population-based 
registries or accrual of death certificates (n=1,401, 68%) while the remaining deaths were 
identified via next-of-kin contact (n=389, 19%) or through other mechanisms, including 
review of obituaries (n=263, 13%). As anticipated, MSI-high compared to MS-stable/MSI-
low was associated with lower risk of all-cause mortality (HR: 0.68; 95% CI: 0.57 to 0.81), 
adjusted for stage, age, sex, BMI, smoking and study center, whereas BRAF-mutation 
compared to BRAF-wildtype was associated with higher risk of all-cause mortality (HR: 
1.32; 95% CI: 1.10 to 1.59), adjusted for MSI-status, stage, age, sex, BMI, smoking and 
study center.
Table 1 shows socio-demographic, pre-diagnostic behavioral/lifestyle factors, and clinical 
factors for the study sample overall and stratified by pre-diagnosis recent BMI. Persons who 
were obese (BMI > 30 kg/m2), compared to persons who had normal BMI (18.5 to 24.9 
kg/m2), were more likely to be men, ate more red meat, were less educated, were less likely 
to be current smokers, and were less physically active.
When testing the proportional hazards assumption, an interaction was observed for 
categorical BMI (excluding underweight BMI) and time (P: 0.003); however, after 
excluding the first 2 years of follow-up, the P-value for the interaction was no longer 
statistically significant. From visually inspecting the Kaplan-Meier curves for categorical 
pre-diagnosis recent BMI (Figure 1), it appears that the interaction between BMI and time is 
caused in the first 2 years of follow-up wherein the survival curves for the BMI categories 
essentially overlap. After approximately 2 or 3 years of follow-up, the curves begin to 
diverge, with the obese category showing the most marked decline (log rank p-value: 
<0.0001).
Table 2 shows the associations of pre-diagnosis recent BMI, BMI at age 20 years, and adult 
weight change with all-cause and colorectal-cancer-specific mortality. For women and men 
combined, there was a clear dose-response association between pre-diagnosis recent BMI 
and all-cause mortality: compared to a normal BMI, overweight, class I obesity, class II 
obesity, and class III obesity were associated with 12%, 19%, 43% and 52% higher risks of 
mortality from all causes, respectively. The same general pattern was shown for BMI at age 
20 years and all-cause mortality, albeit with less precision. Adult weight change, per 5 kg, 
was associated with a marginally higher risk of all-cause mortality. Generally similar results 
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were obtained for colorectal-cancer-specific mortality, although confidence intervals were 
wider with the smaller numbers of outcomes.
The joint impact of pre-diagnosis recent BMI and MSI status is shown in Table 3. Compared 
to persons with MS-stable/MSI-low and normal BMI, risk of death was higher for MS-
stable/MSI-low and obesity (HR: 1.32), not statistically-significantly lower for MSI-high 
and normal BMI (HR: 0.86), and essentially the same for MSI-high and obesity (HR: 1.00).
As shown in Figure 2, there was no compelling evidence that the association between recent 
BMI per 5 kg/m2 and all-cause mortality differed by site in the colon or rectum, stage, age at 
diagnosis, physical activity, red meat intake, or time from diagnosis to enrollment. Pre-
diagnosis recent BMI was associated with higher risks of all-cause mortality among persons 
with both MS-stable/MSI-low (HR: 1.10) and MSI-high (HR: 1.24) tumors (P-interaction: 
0.84). Similarly, BMI was associated with all-cause mortality for both strata of BRAF-
mutation status (P-interaction: 0.28), although the CIs for the smaller BRAF-mutation group 
overlapped 1 (HR: 1.10; 95% CI: 0.91 to 1.33). There was some suggestion that risk of 
mortality with BMI might be higher for never smokers than ever smokers, although not 
statistically significant (P-interaction: 0.06). From Figure 3, the relationship between pre-
diagnosis recent BMI and all-cause mortality appears linear (p-linearity: <0.0001). In 
sensitivity analyses that excluded all persons with any missing stage data, the study results 
were essentially unchanged (data not shown), as expected since stage was not a confounder 
or effect modifier in this study.
Discussion
In this prospective cohort of 5,615 persons with invasive colon or rectal cancer, high BMI 
was associated with higher risks of all-cause and colorectal cancer-specific mortality in a 
dose-response and linear manner. Mortality estimates for pre-diagnosis recent BMI were 
consistent in magnitude across strata of sex, MSI, BRAF, stage, and other factors, 
suggesting that pre-diagnostic BMI is a robust indicator for colorectal cancer survival. These 
results also suggest that self-reported adult weight gain is not strongly associated with 
mortality risk for most colorectal cancer survivors.
The association between excess adiposity and colorectal cancer survival has been 
inconsistent despite several expert and consensus reports recommending that cancer 
survivors maintain or achieve a normal weight BMI (41, 42). Part of this inconsistency 
stems from differences in study methodology, predominantly the timing of BMI 
measurement relative to diagnosis (14). Studies that evaluated BMI after diagnosis in 
prospective cohorts (12, 13) or at around the time of diagnosis in adjuvant-treatment trials 
(16–18, 20) showed no evidence of association or only modestly higher risks of mortality 
with high BMI. In most previous studies where BMI was reported a year or more prior to 
colorectal cancer diagnosis, high BMI was associated with higher mortality (12, 13, 15, 24, 
25). The magnitude of this association is similar across studies, including in this study, with 
HRs in the range of 1.2 to 1.5 for the association between obese BMI and all-cause 
mortality.
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Several biological mechanisms may explain the poorer prognosis from high BMI; some 
factors may also relate to colorectal cancer risk, including insulin and its associated growth 
factors and binding proteins, inflammation, oxidative stress and impaired immune 
surveillance. Other, less explored, mechanisms include the potential for obesity to lead to 
the diagnosis of more biologically aggressive tumors, independent of stage and grade (29). 
To this end, higher BMI was associated with higher risk of the more-aggressive MS-stable 
tumors, but not associated with risk of the less-aggressive MSI-high tumors, in a previous 
study from the Colon-CFR (8), suggesting that BMI may not be as relevant in the context of 
developing an MSI-high tumor. In this analysis, we extend those findings to show BMI is 
relevant to colorectal cancer survival for patients with both MS-stable and MSI-high tumors, 
although the MSI-high group compared to the MS-stable group still maintains a prognostic 
advantage at each level of BMI. The role of BMI with colorectal cancer risk and survival 
according to various molecular markers has been examined in the Nurses’ Health Study and 
the Health Professionals Follow-up Study. Using this extensive molecular pathologic 
epidemiology (MPE) resource, BMI was differentially associated with risks of colorectal 
cancer according to CTNNB1 (43) and FASN (11) expression status. Further work from this 
MPE resource showed that BMI differentially influences survival for colorectal cancer 
patients when groups are stratified by expression patterns of TP53 (44), CTNNB1 (45), p21 
(46), STMN-1 (47), p27 (48), and FASN (49). Given the complex nature of colorectal 
cancer and the myriad of potential interactions that may occur between adiposity-markers 
and the tumor microenvironment, further work is clearly needed to better understand the 
biologic role of obesity on colorectal cancer risk and prognosis.
Clinical factors generally do not seem to explain the association between high BMI and 
poorer prognosis: compared to participants with a normal BMI enrolled on a clinical trial for 
colon cancer adjuvant treatment, obese participants had lower rates of leukopenia, nausea 
and grade 3 or 4 toxicity and no differences were noted for emesis, diarrhea, stomatitis, and 
treatment related death (16). Similarly, in a study of rectal cancer patients, BMI did not 
modify rates of nausea, emesis or diarrhea; however, obese persons were less likely to 
experience leukopenia, neutropenia, stomatitis, and any grade 3 or 4 toxicity (17).
One limitation of this study is that post-diagnosis body weight and potential confounders 
(e.g., physical activity and diet) were not comprehensively available. Body weight can 
change after diagnosis, due to the disease itself or as an effect of treatment. In the largest of 
the studies that had both pre- and post-diagnosis BMI for colorectal cancer survivors, pre-
diagnosis BMI, but not post-diagnosis BMI, was associated with higher risk of mortality 
(12). This attenuation of association probably reflects illness-associated weight loss in the 
post-diagnosis setting (12, 50). With the evidence accumulated thus far, and given the 
established relationship between BMI and several causes of death beyond colorectal cancer, 
it seems reasonable to conclude that pre-diagnosis BMI is associated with higher risk of 
death among colorectal cancer survivors. Further, because the post-diagnosis BMI analyses 
are likely confounded by illness, studies are needed that can distinguish between weight loss 
from illness/cachexia versus lifestyle modification (e.g., physical activity and/or caloric 
restriction) to clarify the prognostic role of weight-loss interventions for overweight/obese 
colorectal cancer survivors. Importantly, several observational studies have suggested that 
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higher post-diagnosis physical activity among colorectal cancer survivors is associated with 
improved prognosis independent of BMI (13, 51, 52).
This study lacked detailed data on treatment, toxicity, surgical complications, and cancer 
recurrence; however, a recent pooled study of over 25,000 colon cancer patients enrolled on 
adjuvant treatment trials showed that adjuvant treatment did not confound or modify the 
association between BMI and all-cause mortality (20). Dose capping for adjuvant therapy 
among obese colorectal cancer patients was demonstrated to have no material influence on a 
variety of outcomes, including colon cancer recurrence and all-cause mortality (18). Another 
limitation of this study was that participants were asked to recall their body weight before 
cancer diagnosis. Cross-sectional data show that self-reported BMI values are typically 
slightly lower than directly measured values (53); under-reporting of self-reported BMI may 
overestimate associations of overweight BMI with risk of mortality and concurrently 
underestimate the association for obese BMI. Good-to-excellent agreement was reported, 
however, in studies with similar demographic characteristics to this study for self-reported 
and directly measured values of height and weight (54, 55). Furthermore, prospective studies 
with height and weight data reported many years prior to colorectal cancer diagnosis (12, 13, 
15, 24, 25) have shown similar associations to those reported in this study, providing some 
re-assurance that recall bias is less likely to be a major concern.
Distinct advantages of this study include its large sample size and the availability of data on 
MSI, BRAF, smoking, and other potential effect modifiers, which allowed for the 
examination of whether the sub-group differences often observed in incidence studies 
applied to prognosis. The meta-analysis by Parkin et al. (14) identified summary HRs for the 
association between BMI per 5 kg/m2 and all-cause mortality by sex (women, HR: 1.16; 
men, HR: 1.07) that were similar to our findings, suggesting that sex is not an effect 
modifier in prognosis studies, in contrast to results from incidence studies where 
associations are typically higher for men than women (2–5). Few studies have examined 
whether risk of mortality with BMI differed by site within the colorectum (12, 24, 25). In the 
current study, we observed essentially the same risk estimates for the colon and rectum. The 
Cancer Prevention Study-II Nutrition Cohort observed stronger associations between BMI 
and mortality for persons diagnosed with rectal than colon cancers (12), similar to the results 
from Haydon et al. (25). Doria-Rose et al. showed that BMI was associated with risk of 
mortality among women diagnosed with colon, but not rectal, cancer (24). We are not aware 
of a clear explanation for these discrepant findings; it is plausible that chance is playing a 
role. Future work, preferably with pooled data from multiple prospective studies, will be 
needed to clarify this issue.
In this study, there were no statistical interactions between pre-diagnostic BMI and BRAF or 
MSI, suggesting that high BMI is associated with worse prognosis regardless of these tumor 
subtypes. For patients with MSI-high tumors, this observation may be clinically relevant, 
particularly for stage II disease because MSI-high status is recommended to identify patients 
who do not need or benefit from 5-FU-based adjuvant therapy (56). Accordingly, obesity in 
stage II colon cancer patients has potential implications for treatment that should be 
considered in future studies. We report suggestive, albeit not statistically significant, 
evidence that smoking may modify the link between BMI and all-cause mortality. This 
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phenomenon occurs in more general populations (57–59) and is attributed to smoking-dose 
being correlated with lower BMI and with higher risk of death. It is important to note that 
several sub-group comparisons were made in this analysis and these results may be due to 
chance.
In conclusion, in this cohort of colorectal cancer survivors, high pre-diagnosis BMI was 
associated with higher all-cause and colorectal-cancer-specific mortality; these associations 
were consistent across strata of sex, tumor molecular phenotype, TNM summary stage, site 
in the colorectum, age at diagnosis, and red meat intake. Importantly, high BMI attenuated 
the survival advantage otherwise observed among persons with MSI-high tumors. Further 
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Kaplan-Meier survival curve for death from all-causes for men and women diagnosed with 
colorectal cancer in the Colon Cancer Family Registry, 1997 to 2012.
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Relative risks (RRs) and 95% CIs for deaths from all causes per 5 kg/m2 of BMI for persons 
diagnosed with colorectal cancer in the Colon Cancer Family Registry, 1997 to 2012.
P-values for heterogeneity are calculated by comparing the likelihood ratio statistic from 
models with and without interaction terms. Models are adjusted for sex, TNM stage, 
cigarette smoking, Colon-CFR study site, and age at diagnosis (strata statement).
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Restricted cubic spline analysis of recent pre-diagnosis BMI and all-cause mortality for men 
and women diagnosed with colorectal cancer in the Colon-Cancer Family Registry, 1997 to 
2012.
Solid line indicates hazard ratio while dashed line indicates 95% confidence intervals.
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Table 3
Joint associations of body mass index and microsatellite instability status on all-cause mortality: the Colon 
Cancer Family Registry, 1997 to 2012.
MS-stable and MSI-low MSI-high
Deaths/Person years Multivariable HR (95% CI)* Deaths/Person years Multivariable HR (95% CI)*
Recent BMI
 18.5–<25 425/7,530 1.00 (ref) 60/1,556 0.86 (0.65–1.14)
 25–<30 532/8,419 1.19 (1.04–1.36) 44/1,547 0.58 (0.42–0.80)
 ≥30 376/5,481 1.32 (1.14–1.53) 47/1,062 1.00 (0.74–1.37)
*
Adjusted for sex, TNM stage, cigarette smoking, Colon-CFR study site, and age at diagnosis (strata statement).
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